-
Bydureon FDA Action Date Set For January 28, 2012
Wednesday, August 10, 2011 - 4:18pm | 228Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has acknowledged the companies' BYDUREON™ (exenatide extended-release for injectable suspension) resubmission. The FDA...
-
Puts Purchased on Sanofi
Wednesday, August 10, 2011 - 11:05am | 135Shares of Sanofi (NYSE: SNY) are lower on the session by 6.01%, currently trading at $32.06. The stock has been moving largely lower over the past two months and is currently trading below the 50-day moving average. Options traders are buying puts on the name today. A short while ago the 2011...
-
Embrace Your Inner Spock: Three Questions Investors Should be Asking
Wednesday, August 10, 2011 - 10:33am | 858Congratulations, you've just lived through the sixth-worst day in the history of the U.S. stock market. The Dow Industrials fell 634 points on Monday in response to Standard & Poor's downgrade of the United States' credit rating, and two days later the volatility continues. After a day like...
-
ISS Recommends Forest Shareholders Vote For Company's Entire Slate of Ten Board Nominees
Wednesday, August 10, 2011 - 10:15am | 153Forest Laboratories, Inc. (NYSE: FRX) commented on today's report by leading proxy advisory service Institutional Shareholder Services, recommending that shareholders vote the WHITE proxy card to elect all ten of Forest's director nominees at the Company's Annual Meeting of Shareholders, which will...
-
Options Brief: Adolor
Wednesday, August 10, 2011 - 10:07am | 80Shares of Adolor (NASDAQ: ADLR) are higher on the session by 0.45%, trading at $2.22. Overall call volume is now running at 7.78x the daily average, with 0% of all calls traded being purchases on the offer. 3,035 contracts have traded on the session so far. Adolor Corporation is a...
-
UPDATE: Zacks Upgrades DepoMed from Neutral to Outperform
Wednesday, August 10, 2011 - 9:56am | 119Zacks Small Cap Research has published a report on Depomed (NASDAQ: DEPO) upgrading the company's stock from Neutral to Outperform. In the report, Zacks wrote, "However, Depomed, with its solid cash position ($164 million as of June 2011), two approved drugs in Glumetza and Gralise, and our...
-
Zacks Upgrades Depomed To Outperform, $10 PT
Wednesday, August 10, 2011 - 9:09am | 24Zacks Investment Research has upgraded Depomed (NASDAQ: DEPO) from Neutral to Outperform with a $10 price target.
-
UPDATE: Piper Jaffray Upgrades Endo Pharmaceuticals to Overweight
Wednesday, August 10, 2011 - 9:06am | 103Piper Jaffray is out with its report today on Endo Pharmaceuticals (NASDAQ: ENDP), upgrading ENDP to Overweight from Neutral. In its report, Piper Jaffray writes, "We are upgrading Endo to Overweight from Neutral and raising our price target to $46 from $44. With management guiding to a 2011 EPS...
-
Abbott Receives U.S. FDA Approval for RX Herculink Elite Renal Stent System for Treatment of Renal Artery Disease
Wednesday, August 10, 2011 - 9:01am | 212Abbott (NYSE: ABT) today announced it has received U.S. Food and Drug Administration approval for the RX Herculink Elite Renal Stent System for the treatment of renal artery stenosis (narrowing of the main arteries supplying blood to the kidneys) in patients with uncontrolled hypertension (high...
-
GNS Healthcare Announces Collaboration With Bristol-Myers Squibb
Wednesday, August 10, 2011 - 8:31am | 40GNS Healthcare today announced that it has entered into a collaboration with Bristol-Myers Squibb Company (NYSE: BMY) focused on the discovery of novel disease biology and biomarkers in the area of immuno-inflammation.
-
UPDATE: Oppenheimer Lowers PT on Simcere Pharmaceutical Group to $12.50
Wednesday, August 10, 2011 - 8:27am | 75Oppenheimer is out with its report today on Simcere Pharmaceutical Group (NYSE: SCR), lowering its PT to $12.50. In its report, Oppenheimer writes, "We believe price cut risk remains for the rest of the year and have changed our FY2011/2012 revenue and EPS forecasts. We lowered our target price to...
-
J.P. Morgan Reiterates Overweight on Pfizer
Wednesday, August 10, 2011 - 8:16am | 126J.P. Morgan is out with its report today on Pfizer (NYSE: PFE), reiterating Overweight. In its report, J.P. Morgan writes, "Against the backdrop of a difficult market, Pfizer clearly stands out as the defensive play in our coverage universe, offering an attractive mix of 1) inexpensive valuation (...
-
Adolor Corporation Announces Positive Results from Phase 2 Program in OIC
Wednesday, August 10, 2011 - 8:09am | 88Adolor Corporation (Nasdaq: ADLR) today announced positive, statistically significant top line results from its two Phase 2 studies of ADL5945 in chronic non-cancer pain patients with opioid-induced constipation. ADL5945, a peripherally-acting mu opioid receptor antagonist, is an investigational...
-
Watson's Rosuvastatin Zinc Tablets Receive Tentative FDA Approval
Wednesday, August 10, 2011 - 8:03am | 174Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that its subsidiary, Watson Laboratories, Inc., has received tentative approval from the United States Food and Drug Administration for its rosuvastatin zinc 5, 10, 20 and 40 mg tablets. Watson's rosuvastatin zinc tablets are a new salt form...
-
Piper Jaffray Upgrades Endo Pharmaceuticals To Overweight, Raises PT To $46
Wednesday, August 10, 2011 - 7:35am | 28Piper Jaffray has upgraded Endo Pharmaceuticals (NASDAQ: ENDP) from Neutral to Overweight and has raised the price target from $44 to $46.